CERS - Cerus Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Cerus Corporation

2550 Stanwell Drive
Concord, CA 94520
United States

Full Time Employees240

Key Executives

NameTitlePayExercisedYear Born
Mr. William M. GreenmanPres, CEO & Director1.06M753.2k1967
Dr. Laurence M. CorashCo-Founder & Chief Scientific Officer616.27k122.5k1944
Mr. Kevin D. GreenVP of Fin. & CFO598.28k681.85k1972
Dr. Richard J. BenjaminChief Medical Officer589.22k243.98k1960
Mr. Vivek K. JayaramanChief Commercial Officer669.87kN/A1975
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Corporate Governance

Cerus Corporation’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.